Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 07 Jun 2019 Status changed from active, no longer recruiting to completed.
- 01 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2019.